Metz L D, Seidler F J, McCook E C, Slotkin T A
Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710, USA.
J Mol Cell Cardiol. 1996 May;28(5):1033-44. doi: 10.1006/jmcc.1996.0096.
Although thyroid hormone is obligatory for the development of cardiac beta-adrenergic receptors, it is difficult to assign a specific role for the hormone in receptor ontogeny because beta-receptor expression is affected similarly in the adult. We have determined whether thyroid hormone plays a role in receptor development by evaluating alpha 1-adrenergic receptors, which in the adult are downregulated by thyroid hormone. Propylthiouracil given from gestational day 17 through postnatal day 5 caused significant deficits in the number of alpha 1-receptors and values resolved to normal in parallel with hormone level recovery. When propylthiouracil was administered later (postnatal days 11 through 15) only a transient deficit in alpha 1-receptor binding was seen; hyperthyroidism (triiodothyronine) could still evoke stimulation of receptor expression at this stage. The effects on receptor expression were distinguished from general effects on cell differentiation by examining alpha 2-receptors, which disappear over the first three postnatal weeks; delayed differentiation caused by propylthiouracil would slow the decline in alpha 2-receptors, whereas accelerated differentiation caused by triiodothyronine would hasten the decline. Instead, the effects were similar to those on alpha 1-receptors: perinatal propylthiouracil administration reduced, and neonatal triiodothyronine administration enhanced, alpha 2-receptor binding sites. Thus, thyroid hormone plays a role in the control of cardiac adrenergic receptor expression during a critical development period, with conjoint regulation of the multiple receptor subtypes present within the tissue. As adrenergic stimulation is important in maintaining cardiac function in the perinatal period, alterations of thyroid status during this period can be expected to result in abnormal reactivity and increased perinatal risk.
尽管甲状腺激素对心脏β - 肾上腺素能受体的发育是必不可少的,但由于在成年人中β - 受体的表达受到类似影响,所以很难确定该激素在受体个体发育中的具体作用。我们通过评估α1 - 肾上腺素能受体来确定甲状腺激素是否在受体发育中起作用,在成年人中,α1 - 肾上腺素能受体的表达会被甲状腺激素下调。从妊娠第17天至出生后第5天给予丙硫氧嘧啶会导致α1 - 受体数量显著减少,并且随着激素水平恢复,数值恢复正常。当在出生后较晚时间(出生后第11天至15天)给予丙硫氧嘧啶时,仅观察到α1 - 受体结合的短暂减少;在此阶段,甲状腺功能亢进(三碘甲状腺原氨酸)仍可引起受体表达的刺激。通过检查α2 - 受体来区分对受体表达的影响与对细胞分化的一般影响,α2 - 受体在出生后的前三周内会消失;丙硫氧嘧啶引起的分化延迟会减缓α2 - 受体的下降,而三碘甲状腺原氨酸引起的分化加速会加速α2 - 受体的下降。相反,其影响与对α1 - 受体的影响相似:围产期给予丙硫氧嘧啶会减少,而新生儿给予三碘甲状腺原氨酸会增加α2 - 受体结合位点。因此,甲状腺激素在关键的发育时期对心脏肾上腺素能受体表达的控制中起作用,同时对组织中存在的多种受体亚型进行联合调节。由于肾上腺素能刺激在围产期维持心脏功能中很重要,因此在此期间甲状腺状态的改变可能会导致反应异常并增加围产期风险。